Live Breaking News & Updates on Enhanced Delivery Oligonucleotide

Stay updated with breaking news from Enhanced delivery oligonucleotide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , James Mcarthur , Sarah Sutton , Noel Donnelly , Pepgen Inc , Drug Administration , Regulatory Agency , International Myotonic Dystrophy Consortium , Muscular Dystrophy Association , Duchenne Muscular Dystrophy , Enhanced Delivery Oligonucleotide , Rare Pediatric Disease Designations , Orphan Drug , Dystrophy Association , Repeat Dose Nonclinical Data , Evaluate Safety , Myotonic Dystrophy , Assess Safety , Myotonic Dystrophy Type , Meaningful Activity , Potential Treatment , Three Months Ended March , Private Securities Litigation Reform Act , Consolidated Statements ,

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 13, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe. ....

United States , James Mcarthur , Laurence Watts , Sarah Sutton , Pepgen Inc , Drug Administration , Gilmartin Group , Orphan Drug Act , Rare Pediatric Disease , Orphan Drug , Enhanced Delivery Oligonucleotide , Duchenne Muscular Dystrophy , Private Securities Litigation Reform Act ,

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for ...

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ....

United States , Laurence Watts , Sarah Sutton , James Mcarthur , Pepgen Inc , Gilmartin Group , Drug Administration , Orphan Drug Act , Rare Pediatric Disease , Orphan Drug , Enhanced Delivery Oligonucleotide , Duchenne Muscular Dystrophy , Private Securities Litigation Reform Act ,

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

BOSTON, Feb. 07, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe. ....

United States , Sarah Sutton , Laurence Watts , Pepgen Inc , Exchange Commission , Syndicate Department , Leerink Partners , Frazier Life Sciences , Gilmartin Group , Janus Henderson Investors , Laurion Capital Management , Monashee Investment Management , Octagon Capital , Perceptive Advisors , Enhanced Delivery Oligonucleotide ,

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

BOSTON, Jan. 17, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe. ....

United States , Mary Beth Delena , Mary Beth , Laurence Watts , James Mcarthur , Sarah Sutton , Praecis Pharmaceuticals , Pepgen Inc , Trinity College , Alnylam Pharmaceuticals , Meagher Flom , Gilmartin Group , Northeastern University School Of Law , General Counsel , Senior Vice President , Deputy General Counsel , Juris Doctor , Northeastern University School , Enhanced Delivery Oligonucleotide ,